TIGER'S TAKE: On our trading list, the good news keeps coming in for IOVA. A very nice performer this year so far. $IOVAIovance Biotherapeutics price target raised to $30 from $20 at Piper JaffrayPiper Jaffray analyst Joseph Catanzaro raised his price target for Iovance Biotherapeutics to $30 from $20 after spending two days hosting investor meetings with management. The analyst came away optimistic on a near term favorable regulatory update in cervical cancer. The FDA will, at minimum, accept some subset of the current cohort, which would allow enrollment to complete by the end of 2019 and a filing to occur ahead of the planned late-2020 melanoma submission, Catanzaro tells investors in a research note. As a result, he pushed U.S. cervical revenue into 2021. The analyst keeps an Overweight rating on shares of Iovance.Source: (thefly.com) $IOVA, Iovance Biotherapeutics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or comments.